The report analyzes and
presents an overview of "
Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016 "
worldwide.
GlobalData's
clinical trial report, Renal
Cell Carcinoma Global
Clinical Trials Review, H2, 2016" provides an overview of Renal
Cell Carcinoma clinical trials scenario. This report provides top
line data relating to the clinical trials on Renal Cell Carcinoma.
Report includes an overview of trial numbers and their average
enrollment in top countries conducted across the globe. The report
offers coverage of disease clinical trials by region, country (G7 &
E7), phase, trial status, end points status and sponsor type. Report
also provides prominent drugs for in-progress trials (based on number
of ongoing trials). GlobalData Clinical Trial Reports are generated
using GlobalDatas proprietary database - Pharma eTrack Clinical
trials database. Clinical trials are collated from 80+ different
clinical trial registries, conferences, journals, news etc across the
globe. Clinical trials database undergoes periodic update by dynamic
process.
The
report enhances the decision making capabilities and helps to create
an effective counter strategies to gain competitive advantage.
Download
Sample copy of this Report at
Scope
- The report provides a
snapshot of the global clinical trials landscape
- Report provides top level
data related to the clinical trials by Region, Country (G7 & E7),
Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top
companies involved and enlists all trials (Trial title, Phase, and
Status) pertaining to the company
- The report provides all the
unaccomplished trials (Terminated, Suspended and Withdrawn) with
reason for unaccomplishment
- The Report provides
enrollment trends for the past five years
- Report provides latest news
for the past three months
Reasons to buy
- Assists in formulating key
business strategies with regards to investment
- Helps in identifying
prominent locations for conducting clinical trials which saves time
and cost
- Provides top level analysis
of Global Clinical Trials Market which helps in identifying key
business opportunities
- Supports understanding of
trials count and enrollment trends by country in global therapeutics
market
- Aids in interpreting the
success rates of clinical trials by providing a comparative scenario
of completed and uncompleted (terminated, suspended or withdrawn)
trials
- Facilitates clinical trial
assessment of the indication on a global, regional and country level
Table
Of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average
Enrollment by Country 8
Top Five Countries Contributing
to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing
to Clinical Trials in Europe 11
Top Countries Contributing to
Clinical Trials in North America 12
Top Five Countries Contributing
to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing
to Clinical Trials in Central and South America 14
Clinical Trials by G7
Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical
Trials 15
Clinical Trials by Phase in G7
Countries 16
Clinical Trials in G7 Countries
by Trial Status 17
Clinical Trials by E7
Countries: Proportion of Renal Cell Carcinoma to Oncology Clinical
Trials 18
Clinical Trials by Phase in E7
Countries 19
Clinical Trials in E7 Countries
by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status
23
Clinical Trials by End Point
Status 24
Subjects Recruited Over a
Period of Time 25
Clinical Trials by Sponsor Type
26
Prominent Sponsors 27
Top Companies Participating in
Renal Cell Carcinoma Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on
Renal Cell Carcinoma 30
Aug 04, 2016: Gene expression
profile may ID renal cell carcinoma pts unlikely to benefit from
nivolumab 30
Jul 08, 2016: Pfizer Announces
Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT
(sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent
Renal Cell Carcinoma 30
Jun 06, 2016: Preclinical Data
Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent
NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes
to Provide Durable Anti-Tumor Activity 31
Jun 06, 2016: Calithera
Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at
the American Society of Clinical Oncology Annual Meeting 32
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment